Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity

Structure

Volumn 25, Issue 8, 2017, Pages 1275-1285.e4

  Cheng, Robert K Y ^a,b   Segala, Elena ^a   Robertson, Nathan ^a   Deflorian, Francesca ^a   Doré, Andrew S ^a   Errey, James C ^a   Fiez Vandal, Cédric ^a   Marshall, Fiona H ^a   Cooke, Robert M ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

^b PARK InnovAARE   (Switzerland)

Author keywords

adenosine A1 receptor structure; adenosine A2A receptor structure; caffeine; PSB36; theophylline; xanthine

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; LIGAND; THEOPHYLLINE; XANTHINE; XANTHINE DERIVATIVE; ADENOSINE A2A RECEPTOR; CAFFEINE; PROTEIN BINDING;

ARTICLE; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; THERMOSTABILITY; BINDING SITE; CHEMISTRY; ENZYME SPECIFICITY; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR DOCKING;

BINDING SITES; CAFFEINE; HEK293 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; SUBSTRATE SPECIFICITY; THEOPHYLLINE;

EID: 85023630688     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2017.06.012     Document Type: Article

References (51)

1. Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 213–221.
2. Alnouri, M.W., Jepards, S., Casari, A., Schiedel, A., Hinz, S., Müller, C.E., Selectivity is species-dependent: characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. Purinergic Signal. 11 (2015), 389–407.
3. Auchampach, J.A., Jin, X., Moore, J., Wan, T.C., Kreckler, L.M., Ge, Z.-D., Narayanan, J., Whalley, E., Kiesman, W., Ticho, B., et al. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J. Pharmacol. Exp. Ther. 308 (2003), 846–856.
4. Ballesteros, J.A., Weinstein, H., Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25 (1995), 366–428.
5. Caffrey, M., Porter, C., Crystallizing membrane proteins for structure determination using lipidic mesophases. J. Vis. Exp. 3 (2010), 2–6.
6. 2A receptor bound to an engineered G protein. Nature 536 (2016), 104–107.
7. Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., Richardson, D.C., MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 12–21.
8. 2A receptors in Parkinson's disease treatment. Purinergic Signal. 4 (2008), 305–312.
9. 2A antagonists using structure based drug design. J. Med. Chem. 55 (2012), 1898–1903.
10. 2A receptor. Purinergic Signal. 12 (2016), 313–329.
11. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19 (2011), 1283–1293.
12. Dungo, R., Deeks, E.D., Istradefylline: first glogal approval. Drugs 73 (2013), 875–882.
13. Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 486–501.
14. Evans, P.R., Murshudov, G.N., How good are my data and what is the resolution?. Acta Crystallogr. Sect. D Biol. Crystallogr. 69 (2013), 1204–1214.
15. Fenalti, G., Giguere, P.M., Katrich, V., Huang, X.P., Thompson, A.A., Cherezov, V., Roth, B.L., Stevens, R.C., Molecular control of δ-opioid receptor signalling. Nature 506 (2014), 191–196.
16. 1 receptor reveals the basis for subtype selectivity. Cell 168 (2017), 867–877.
17. Hino, T., Arakawa, T., Iwanari, H., Yurugi-Kobayashi, T., Ikeda-Suno, C., Nakada-Nakura, Y., Kusano-Arai, O., Weyand, S., Shimamura, T., Nomura, N., et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482 (2012), 237–240.
18. 2A adenosine receptor bound to an antagonist. Science 322 (2008), 1211–1217.
19. Jacobson, K.A., Gao, Z.-G., Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 5 (2006), 247–264.
20. Kabsch, W., Xds. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 125–132.
21. 1 receptor mediates activity of allosteric enhancers. Mol. Pharmacol. 85 (2014), 301–309.
22. 1 receptor antagonists. J. Med. Chem. 49 (2006), 7119–7131.
23. Klotz, K.-N., Vogt, H., Tawfik-Schlieper, H., Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn Schmiedebergs Arch. Pharmacol. 343 (1991), 196–201.
24. 2A receptor structures reveal common features of GPCR activation. Nature 474 (2011), 521–525.
25. 2A receptors. Mol. Pharmacol. 87 (2015), 907–915.
26. Leone, R.D., Lo, Y.C., Powell, J.D., A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J. 13 (2015), 265–272.
27. Liu, W., Chun, E., Thompson, A.A., Chubukov, P., Xu, F., Katritch, V., Han, G.W., Roth, C.B., Heitman, L.H., IJzerman, A.P., et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337 (2012), 232–236.
28. Lohse, M.J., Klotz, K.-N., Lindenborn-Fotinos, J., Reddington, M., Schwabe, U., Olsson, R.A., 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) – a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 336 (1987), 204–210.
29. 2 adenosine receptor subtypes. Eur. J. Pharmacol. 214 (1992), 199–205.
30. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
31. 1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. PLoS One, 9, 2014, e92727.
32. Müller, C.E., Jacobson, K.A., Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808 (2011), 1290–1308.
33. Müller, C.E., Jacobson, K.A., Xanthines as adenosine receptor antagonists. Handb. Exp. Pharmacol. 200 (2011), 151–199.
34. 1 receptors. Br. J. Pharmacol. 117 (1996), 1645–1652.
35. Olah, M.E., Jacobson, K.A., Stiles, G.L., Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. J. Biol. Chem. 269 (1994), 24692–24698.
36. Pfister, J.R., Belardinelli, L., Lee, G., Lum, R.T., Milner, P., Stanley, W.C., Linden, J., Baker, S.P., Schreiner, G., Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1, 3-dipropyl-8-[2-(5, 6-epoxynorbonyl)]-xanthine. J. Med. Chem. 40 (1997), 1773–1778.
37. 2B signaling in renal fibrosis. Kidney Int. 86 (2014), 685–692.
38. Robertson, N., Jazayeri, A., Errey, J., Baig, A., Hurrell, E., Zhukov, A., Langmead, C.J., Weir, M., Marshall, F.H., The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology 60 (2011), 36–44.
39. Sawynok, J., Adenosine receptor targets for pain. Neuroscience 338 (2016), 1–18.
40. 2B receptor: role in ligand binding and receptor function. Biochem. Pharmacol. 82 (2011), 389–399.
41. 2A receptor through modulation of salt bridge strength. J. Med. Chem. 59 (2016), 6470–6479.
42. 2 adenosine receptors. Biochem. Pharmacol. 85 (2013), 1317–1329.
43. Serrano-Vega, M.J., Magnani, F., Shibata, Y., Tate, C.G., Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form. Proc. Natl. Acad. Sci. USA 105 (2008), 877–882.
44. 2A receptor antagonists and Parkinson's disease. ACS Chem. Neurosci. 2 (2011), 555–567.
45. Terwilliger, T.C., Grosse-Kunstleve, R.W., Afonine, P.V., Moriarty, P.V., Zwart, P.H., Hung, L.-W., Read, R.J., Adams, P.D., Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. Sect. D Biol. Crystallogr. 64 (2008), 61–69.
46. 1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. J. Biol. Chem. 269 (1994), 27900–27906.
47. Ukena, D., Jacobson, K.A., Padgett, W.L., Ayala, C., Shamim, M.T., Kirk, K.L., Olsson, R.O., Daly, J.W., Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett. 209 (1986), 122–128.
48. 1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem 1 (2006), 891–902.
49. Xia, L., de Vries, H., IJzerman, A.P., Heitman, L.H., Scintillation proximity assay (SPA) as a new approach to determine a ligand's kinetic profile. A case in point for the adenosine A1 receptor. Purinergic Signal. 12 (2016), 115–126.
50. 2A adenosine receptor. Science 332 (2011), 322–327.
51. Zhang, C., Srinivasan, Y., Arlow, D.H., Fung, J.J., Palmer, D., Zheng, Y., Green, H.F., Pandey, A., Dror, R.O., Shaw, D.E., et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492 (2012), 387–392.